Indolent Non-Hodgkin's Lymphomas Terminated Phase 3 Trials for Idelalisib (DB09054)

Also known as: Indolent Non-Hodgkin Lymphoma / Indolent Non-Hodgkin's Lymphoma

IndicationStatusPhase
DBCOND0061053 (Indolent Non-Hodgkin's Lymphomas)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01732926Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTreatment
NCT01732913Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTreatment